» Articles » PMID: 24113599

The Effect of a Hospital-wide Urine Culture Screening Intervention on the Incidence of Extended-spectrum β-lactamase-producing Escherichia Coli and Klebsiella Species

Abstract

Objective: Optimal strategies for limiting the transmission of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp (ESBL-EK) in the hospital setting remain unclear. The objective of this study was to evaluate the impact of a urine culture screening strategy on the incidence of ESBL-EK.

Design: Prospective quasi-experimental study.

Setting: Two intervention hospitals and one control hospital within a university health system from 2005 to 2009.

Patients And Intervention: All clinical urine cultures with E. coli or Klebsiella spp were screened for ESBL-EK. Patients determined to be colonized or infected with ESBL-EK were placed in a private room with contact precautions. The primary outcome of interest was nosocomial ESBL-EK incidence in nonurinary clinical cultures (cases occurring more than 48 hours after admission). Changes in monthly ESBL-EK incidence rates were evaluated with mixed-effects Poisson regression models, with adjustment for institution-level characteristics (eg, total admissions).

Results: The overall incidence of ESBL-EK increased from 1.42/10,000 patient-days to 2.16/10,000 patient-days during the study period. The incidence of community-acquired ESBL-EK increased nearly 3-fold, from 0.33/10,000 patient-days to 0.92/10,000 patient-days (P < .001). On multivariable analysis, the intervention was not significantly associated with a reduction in nosocomial ESBL-EK incidence (incidence rate ratio, 1.38 [95% confidence interval, 0.83-2.31]; P - .21).

Conclusions: Universal screening of clinical urine cultures for ESBL-EK did not result in a reduction in nosocomial ESBL-EK incidence rates, most likely because of increases in importation of ESBL-EK cases from the community. Further studies are needed on elucidating optimal infection control interventions to limit spread of ESBL-producing organisms in the hospital setting.

Citing Articles

Limiting the Spread of Multidrug-Resistant Bacteria in Low-to-Middle-Income Countries: One Size Does Not Fit All.

Saliba R, Zahar J, Dabar G, Riachy M, Karam-Sarkis D, Husni R Pathogens. 2023; 12(1).

PMID: 36678492 PMC: 9866331. DOI: 10.3390/pathogens12010144.


The Effect of Infection Precautions on Extended-Spectrum Beta-Lactamase Enterobacteriaceae Colonization Among Nurses in Three Beirut Hospitals.

AbiGhosn J, AlAsmar M, Abboud E, Bailey B, Haddad N Cureus. 2022; 14(4):e23849.

PMID: 35530839 PMC: 9071177. DOI: 10.7759/cureus.23849.


Is systematic fecal carriage screening of extended-spectrum beta-lactamase-producing Enterobacteriaceae still useful in intensive care unit: a systematic review.

Prevel R, Boyer A, Mzali F, Lasheras A, Zahar J, Rogues A Crit Care. 2019; 23(1):170.

PMID: 31088542 PMC: 6518813. DOI: 10.1186/s13054-019-2460-3.


Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

van Duin D, Bonomo R Clin Infect Dis. 2016; 63(2):234-41.

PMID: 27098166 PMC: 4928383. DOI: 10.1093/cid/ciw243.


The Prevalence and Molecular Epidemiology of Multidrug-Resistant Enterobacteriaceae Colonization in a Pediatric Intensive Care Unit.

Suwantarat N, Logan L, Carroll K, Bonomo R, Simner P, Rudin S Infect Control Hosp Epidemiol. 2016; 37(5):535-43.

PMID: 26856439 PMC: 4833541. DOI: 10.1017/ice.2016.16.

References
1.
Schwaber M, Navon-Venezia S, Kaye K, Ben-Ami R, Schwartz D, Carmeli Y . Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006; 50(4):1257-62. PMC: 1426954. DOI: 10.1128/AAC.50.4.1257-1262.2006. View

2.
Lautenbach E, Patel J, Bilker W, Edelstein P, Fishman N . Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001; 32(8):1162-71. DOI: 10.1086/319757. View

3.
Pitout J, Nordmann P, Laupland K, Poirel L . Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005; 56(1):52-9. DOI: 10.1093/jac/dki166. View

4.
Doi Y, Park Y, Rivera J, Adams-Haduch J, Hingwe A, Sordillo E . Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis. 2012; 56(5):641-8. PMC: 3563390. DOI: 10.1093/cid/cis942. View

5.
Souweine B, Traore O, Aublet-Cuvelier B, Bret L, Sirot J, Laveran H . Role of infection control measures in limiting morbidity associated with multi-resistant organisms in critically ill patients. J Hosp Infect. 2000; 45(2):107-16. DOI: 10.1053/jhin.2000.0734. View